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In isolated rat hepatocytes, the phosphoenolpyruvate carboxykinase (PEPCK) inhibitor, quinolinate de- 
creased gluconeogenesis from lactate more than from pyruvate (78 vs 44%). Quinolinate inhibition of 
PEPCK has been reported to be competitive with oxalacetate (OAA), and therefore higher cytosolic OAA 
concentrations could be expected to alleviate quinolinate inhibition of PEPCK and hence reduce its effect 
on gluconeogenesis. With pyruvate as a carbon source, the cytosolic concentration of OAA was higher than 
with lactate (40 vs 9.7 PM). The levels of OAA were manipulated metabolically by adding asparagine (which 
provides more cytosolic OAA through the urea cycle) or oleate (which increases malate efllux from the mito- 
chondria). In each of the 8 conditions studied, quinolinate inhibition of gluconeogenesis was inversely relat- 
ed to the levels of OAA in the cytosol. Quinolinate inhibition of asparagine gluconeogenesis was not due 
to a non-specific effect on urea synthesis. 
Gluconeogenesis Rat hepatocyte Quinolinate Phosphoenolpyruvate carboxykinase 
Asparagine 
Oxalocetate 
1. INTRODUCTION 
Since the discovery in this laboratory [2-51 that 
quinolinate (a metabolite of tryptophan) inhibits 
the gluconeogenic enzyme PEPCK, it has served as 
an extremely useful tool for the selective inhibition 
of this enzyme. The specificity of action has en- 
abled many investigators to study the role of this 
important enzyme in the regulation of gluconeo- 
genesis. One inconsistency in the ,proposed action 
of quinolinate seemed to exist, however; quinoli- 
nate inhibits gluconeogenesis from lactate to a 
Abbreviations: PEPCK, phosphoenololpyruvate car- 
boxykinase; OAA, oxalacetate 
A portion of this work has been presented in preliminary 
form [l] 
greater extent than from pyruvate [6-91. Glucose 
synthesis from either lactate or pyruvate requires 
flux through PEPCK, and therefore if this were 
the only site of quinolinate inhibition, one would 
expect equivalent effects of quinolinate. These ex- 
periments indicated that quinolinate might act at 
another site; such a proposition would obviously 
cloud previous interpretations of quinolinate in- 
hibition data. 
The formation of phosphoenolpyruvate from 
pyruvate during gluconeogenesis nvolves the car- 
boxylation of mitochondrial pyruvate to oxalacetate 
(OAA), which is shuttled to the cytosol in the form 
of malate or aspartate [lo]. The demand for reduc- 
ing equivalents at the glyceraldehyde-3-phosphate 
dehydrogenase step determines the route for the 
transport of C4 acids into the cytosol, where it then 
serves as the substrate for PEPCK. During gluco- 
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neogenesis from lactate, the reducing equivalents 
are formed in the production of pyruvate by lac- 
tate dehydrogenase, and therefore mitochondrial 
OAA is transported into the cytosol as aspartate. 
On the other hand, when pyruvate is the substrate, 
reducing equivalents must be supplied by the 
mitochondria via conversion of OAA to malate, 
followed by malate export to the cytosol and 
subsequent reoxidation of malate to OAA gene- 
rating the needed NADH. 
Based on these distinct pathways for lactate and 
pyruvate gluconeogenesis, the different degrees of 
quinolinate inhibition observed with these two 
substrates might be explained by quinolinate ac- 
tion at a secondary site unique to the lactate 
pathway. Quinolinate has been reported to inhibit 
purified aspartate aminotransferase [ 111, but this 
action does not account for the differential effect 
on gluconeogenesis as is apparent from ethanol ox- 
idation studies performed by Crow et al. [8]. The 
rate of ethanol oxidation is known to be limited by 
the transfer of reducing equivalents into the 
mitochondria via the Borst cycle. The enzymes in- 
volved in this pathway (cytosolic and mitochon- 
drial aspartate aminotransferases and malate 
dehydrogenases) are the same enzymes utilized to 
shuttle OAA out of the mitochondria during 
gluconeogenesis from either lactate or pyruvate. 
Ethanol oxidation (in the presence of lactate to 
generate Borst cycle intermediates) is insensitive to 
quinolinate. This indicates that none of the en- 
zymes involved in the Borst cycle, and consequent- 
ly none of the enzymes unique to the gluconeogenic 
pathways of pyruvate or lactate, are sufficiently 
affected by quinolinate to explain the differential 
actions of this inhibitor. The distinct responses of 
lactate and pyruvate gluconeogenesis to quinolinate 
therefore cannot be attributed to a site of quino- 
linate action specific to one of the two pathways. 
Here, we suggest hat the inhibition of gluconeo- 
genesis by quinolinate is dependent on the cytosolic 
concentration of the PEPCK substrate, OAA. 
MATERIALS AND METHODS 
2.1. Source of reagents 
Quinolinate (pyridine-2,3-dicarboxylic acid) was 
obtained from Aldrich. 3-Mercaptopicolinate was 
a gift from Smith, Kline, and French, Inc. All 
other reagents were from Sigma. 
2.2. Hepatocyte isolation and incubation 
Male Sprague-Dawley rats (250-300 g) were 
fasted 24 h prior to use. Hepatocytes were pre- 
pared by a modification [12] of the method of 
Berry and Friend [ 131. Preparation and suspension 
of cells were performed in the absence of added 
Ca2+; CaClz was subsequently added to the in- 
cubation medium (final concentration, 2.4 mM) 
except where noted. Greater than 90% of the cells 
were judged viable based on the exclusion of 
trypan blue. Hepatocytes (40 mg wet wt) were in- 
cubated in 1 ml of Krebs-Henseleit buffer contain- 
ing 1.5% defatted bovine serum albumin [14] and 
2.4 mM CaC12 at 37°C in stoppered 20 ml scintilla- 
tion vials flushed with 95 : 5% 02 : COz. Quinoli- 
nate, at 4.8 mM, (or saline in controls) was added 
15 min prior to the addition of gluconeogenic 
substrates (10 ~1) to facilitate uptake of the in- 
hibitor [ 151. Hepatocytes were subsequently in- 
cubated for 40 min with substrates, during which 
time the rates of gluconeogenesis were linear. In all 
cases, the endogenous rate of gluconeogenesis (in 
the absence of added substrates) was subtracted 
from the rate in the presence of substrate. 
2.3. Metabolite determinations 
Cellular metabolites were measured following 
termination of incubations with perchloric acid. 
Glucose was determined using the glucose oxidase 
method [16] and both lactate [17] and pyruvate 
[18] were assayed in extracts of incubated whole 
cells. Previous studies have shown that similar 
ratios of lactate to pyruvate are found in the 
cytosol, whole cells, or the suspending medium 
[19,20]. Urea was measured in deproteinized ex- 
tracts using urease and glutamate dehydrogenase 
WI. 
Cytosolic malate concentrations were determined 
by subtracting mitochondrial contents (separated 
by a modification [22] of the method of Zuuren- 
donk and Tager [23]) from total cellular malate 
levels. Briefly, following short incubations (ap- 
prox. 15 s) in the absence or presence of digitonin, 
cells were centrifuged through an oil layer into per- 
chloric acid. Butyl malonate (1 mM) was included 
during the brief incubation to inhibit malate 
transport across the mitochondrial membrane. The 
mitochondrial and total levels of malate were 
subsequently measured fluorometrically in neutra- 
lized perchloric acid extracts [24]. 
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Cytosolic OAA was calculated assuming that 
malate dehydrogenase and lactate dehydrogenase 
catalyse near-equilibrium reactions [25,26] and 2 
ml cytosolic water per g dry wt cells [27]. 
3. RESULTS AND DISCUSSION 
In agreement with previous reports [a-9], quino- 
linate inhibited the rate of gluconeogenesis from 
lactate more than it did if pyruvate served as the 
carbon source (78.0 vs 42.1070, table 1). Using a 
10: 1 ratio of lactate to pyruvate, the degree of 
quinolinate inhibition was intermediate between 
the effects observed using either substrate alone. 
Since an effect of quinolinate on the enzymes 
specific to either of the gluconeogenic pathways 
for these substrates can be excluded (see above), a 
model was required to explain these results. 
One hypothesis that has been advanced is that 
quinolinate inhibition of gluconeogenesis might be 
dependent upon the concentration of OAA in the 
cytosol [8]. Consistent with this notion, kinetic 
studies on purified PEPCK have indicated that 
quinolinate inhibition of PEPCK is competitive 
[28] with OAA, although noncompetitive inhibi- 
tion has also been observed [29]. The rate of 
gluconeogenesis is not necessarily dependent on 
cytosolic OAA levels [30], and therefore the ap- 
plication of the kinetic studies with the isolated en- 
zyme is unclear. Nevertheless, we examined the 
possibility that quinolinate inhibition of glucose 
synthesis could be related of cytosolic OAA con- 
centrations. 
3-Mercaptopicolinate, a structural analog of 
quinolinate, inhibits PEPCK through a parallel 
mechanism greatly enhanced by the presence of 
Fe’+ [26,29]. Consistent with previous observa- 
tions [30], 3-mercaptopicolinate was a more potent 
inhibitor of lactate than pyruvate gluconeogenesis 
(76 vs 54%). We have focussed our study on 
quinolinate inhibition of gluconeogensis; however 
these results may have similar applications to the 
effects of 3-mercaptopicolinate. 
Pyruvate is likely to produce high levels of 
cytosolic OAA because of the near equilibrium 
nature of both malate dehydrogenase and lactate 
dehydrogenase reactions. When pyruvate is the 
gluconeogenic substrate, some of it is converted to 
Table 1 
Quinolinate inhibition of gluconeogenesis from different substrates 
Substrates Rate of gluconeogenesis % inhibition 
(Ctmol/min per g wet wt) by quinolinate 
Control + quinolinate 
Lactate 
Lactate + oleate 
Lactate + asparagine 
Lactate + pyruvate 
(1 mM) 
Pyruvate 
Pyruvate + oleate 
Pyruvate + asparagine 
Asparagine 
0.432 f 0.010 
0.784 f 0.017 
0.530 + 0.008 
0.473 f 0.016 
0.415 f 0.008 
0.804 ztz 0.012 
0.493 * 0.011 
0.232 f 0.008 
0.095 f 0.007 78.0 
0.267 + 0.008 66.0 
0.217 + 0.007 59.2 
0.232 f 0.008 50.9 
0.241 f 0.006 42.1 
0.490 f 0.010 38.8 
0.320 f 0.009 35.1 
0.167 f 0.005 28.0 
Isolated hepatocytes from 24 h fasted rats were incubated with 4.8 mM 
quinolinate (or saline in controls) for 15 min prior to the addition of 
substrates. All incubations were in Krebs-Henseleit buffer containing 1.5% 
defatted bovine serum albumin and 2.4 mM Ca2+ as detailed in section 2. 
Initial concentrations of the added substrates were: 10 mM lactate; 10 mM 
pyruvate (unless otherwise indicated); 5 mM asparagine; and 1 mM oleate. 
Hepatocytes were incubated with substrates for 40 min and glucose produc- 
tion was measured as described in section 2. Results are expressed as the 
means + SE of duplicates from 4 different hepatocyte preparations 
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lactate thereby oxidizing the cytosol. This oxidized 
cytosol shifts the equilibrium of malate dehydro- 
genase towards OAA formation leading to the 
generation of high cytosolic OAA concentrations. 
The presence of high concentrations of lactate 
however, produces a far less oxidized cytosol, and 
therefore the malate dehydrogenase equilibrium no 
longer favors OAA production as it does with 
pyruvate. Consequently, pyruvate would be ex- 
pected to produce higher OAA concentrations 
than lactate which could account for its lower sen- 
sitivity to quinolinate. 
To determine the dependency of quinolinate in- 
hibition on OAA levels, the cytosolic concentra- 
tion of OAA was manipulated while the magnitude 
of glucose synthesis inhibition by quinolinate was 
assessed. The instability of OAA in solution 
renders direct addition of OAA to cells undesir- 
able. Asparagine and oleate were chosen to in- 
crease the cytosolic OAA concentration. Aspara- 
gine is metabolized by cytosolic asparaginase [31] 
to aspartate and ammonia which can then be con- 
verted to urea and OAA via the urea cycle. Oleate 
would also be expected to raise OAA levels in the 
cytosol by providing a more reduced mitochondria 
LETTERS September 1985 
favoring malate efflux into the cytosol thereby in- 
creasing OAA production through mass-action on 
cytosolic malate dehydrogenase. These compounds 
were therefore added with pyruvate or lactate to 
increase cytosolic OAA levels to determine whether 
the inhibitory effects of quinolinate would be 
diminished. 
Oleate or asparagine stimulated glucose syn- 
thesis from either lactate or pyruvate (table 1). In 
each case the addition of asparagine or oleate also 
diminished the degree of quinolinate inhibition. 
When asparagine was the only substrate for 
gluconeogenesis, the weakest effect of quinolinate 
was observed (only 28% inhibition). 
The role of Ca2+ in quinolinate inhibition of 
glucose synthesis was explored by incubating 
hepatocytes in the absence of added Ca2+. Under 
these conditions, identical degrees of inhibition 
were observed for the different substrate combina- 
tions (not shown), however the absolute rates of 
gluconeogenesis were lower, in agreement with a 
previous report [32]. 
The cytosolic concentrations of OAA were 
assessed to determine if they correlated with the 
theoretical predictions discussed above. OAA is 
Table 2 
Calculated cytosolic oxalacetate concentrations from cytosolic malate and 
the lactate/pyruvate ratio in response to different substrates 
Substrates Cytosolic 
malate 
concentration 
(mM) 
Lactate/pyru- Calculated 
vate ratio cytosolic 
OAA concen- 
tration &M) 
Lactate 0.309 f 0.011 8.04 f 0.14 9.7 f 0.41 
Lactate + oleate 0.860 + 0.071 11.2 + 0.46 19.4 f 1.5 
Lactate + asparagine 0.643 * 0.021 6.71 + 0.41 24.2 f 1.8 
Lactate + pyruvate 
(1 mM) 1.27 f 0.092 10.1 + 0.87 32.0 + 2.8 
Pyruvate 0.430 * 0.012 2.69 f 0.21 40.4 l?r 3.1 
Pyruvate + oleate 0.829 f 0.065 4.40 * 0.33 47.6 f 3.4 
Pyruvate + asparagine 0.588 f 0.028 2.59 * 0.22 57.4 * 4.7 
Asparagine 0.529 f 0.038 2.11 + 0.26 69.8 f 6.6 
Substrate concentrations are identical to those in table 1. Hepatocytes were 
incubated with 4.8 mM quinolinate for 15 min prior to the addition of 
gluconeogenic substrates. Determinations of lactate, pyruvate, and the 
separation and measurement of cytosolic malate are outlined in section 2. 
Cytosolic OAA was calculated based on near-equilibrium assumptions 
described insection 2. Results are expressed as the means f SE for duplicate 
determinations from 4 separate hepatocyte preparations 
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Fig. 1. Correlation between cytosolic OAA concentration 
and quinolinate inhibition of gluconeogenesis. Data 
were compiled from the experiments described in tables 
1 and 2. 
very unstable and is present in small amounts 
rendering its direct measurement in cell extracts ex- 
tremely difficult. An accepted alternative is to 
calculate the cytosolic concentration of OAA 
assuming near-equilibrium for the lactate and 
malate dehydrogenases reactions [25,26] and using 
measured concentrations of lactate, pyruvate and 
cytosolic malate (see section 2). As predicted, 
oleate, which increases malate efflux from the 
mitochondria, increased the levels of malate in the 
cytosol when added in combination with either lac- 
tate or pyruvate (table 2). Similarly, asparagine, 
which forms cytosolic fumarate through the urea 
cycle, elevated cytosolic malate concentrations. 
More cytosolic OAA was formed during gluco- 
neogenesis from pyruvate than lactate, in support 
of our hypothesis. Furthermore, both oleate and 
asparagine increased the cytosolic concentration of 
OAA measured during either lactate or pyruvate 
gluconeogenesis (table 2). The values for cytosolic 
OAA are within the range of the reported K,,, for 
PEPCK of 1 l-l 10 PM, depending on assay condi- 
tions [33]. We also confirm previous reports that 
the rate of gluconeogenesis i  not directly deter- 
mined by the cytosolic concentration of OAA. 
In tables 1 and 2, the substrates for gluconeo- 
genesis are listed in decreasing order of quinolinate 
effectiveness and increasing concentrations of 
OAA, respectively. It is apparent hat the degree of 
quinolinate inhibition is reduced as the cytosolic 
concentration of OAA increase (fig.1). 
Table 3, 
Effect of quinolinate on, urea synthesis in isolated 
hepatocytes 
Substrates Urea synthesis 
(ccmol/min per g wt) 
Control + quinolinate 
Pyruvate + asparagine 1.37 z!z 0.06 1.33 f 0.08 
Lactate + asparagine 1.69 f 0.08 1.72 + 0.08 
Asparagine 1.60 f 0.10 1.64 f 0.11 
Urea production was measured as described in section 2 
after incubating hepatocytes with substrate concentra- 
tions indicated in table 1. All data presented are the 
means f SE of duplicates from 4 separate hepatocyte 
preparations 
Since it was possible that quinolinate inhibition 
of gluconeogenesis from asparagine, where OAA 
is generated through the urea cycle, might be the 
result of a site of quinolinate action on urea syn- 
thesis, this parameter was examined. Quinolinate 
had no effect on the rate of urea formation from 
asparagine, either alone, or in the presence of 
pyruvate or lactate (table 3). 
It is evident hat the level of OAA can dictate the 
sensitivity of gluconeogenesis to quinolinate. The 
levels of OAA were manipulated through two in- 
dependent mechanisms and a close inverse correla- 
tion with quinolinate inhibition was observed. It 
appears that the differential sensitivities of lactate 
and pyruvate gluconeogenesis can be accounted 
for by the differences in their production of OAA; 
no other site for quinolinate action need be in- 
voked. In light of the similar mode of action of 
3-mercaptopicolinate, it is probable that parallel 
conclusions may be drawn for that inhibitor. 
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